Dopamine-and cAMP-regulated phosphoprotein of molecular weight 32 kDa (DARPP-32 or PPP1R1B) has been of interest in schizophrenia owing to its critical function in integrating dopaminergic and glutaminergic signaling. In a previous study, we identified single-nucleotide polymorphisms (SNPs) and a frequent haplotype associated with cognitive and imaging phenotypes that have been linked with schizophrenia, as well as with expression of prefrontal cortical DARPP-32 messenger RNA (mRNA) in a relatively small sample of postmortem brains. In this study, we examined the association of expression of two major DARPP-32 transcripts, full-length (FL-DARPP-32) and truncated (t-DARPP-32), with genetic variants of DARPP-32 in three brain regions receiving dopaminergic input and implicated in schizophrenia (the dorsolateral prefrontal cortex (DLPFC), hippocampus and caudate) in a much larger set of postmortem samples from patients with schizophrenia, bipolar disorder, major depression and normal controls (4700 subjects). We found that the expression of t-DARPP-32 was increased in the DLPFC of patients with schizophrenia and bipolar disorder, and was strongly associated with genotypes at SNPs (rs879606, rs90974 and rs3764352), as well as the previously identified 7-SNP haplotype related to cognitive functioning. The genetic variants that predicted worse cognitive performance were associated with higher t-DARPP-32 expression. Our results suggest that variation in PPP1R1B affects the abundance of the splice variant t-DARPP-32 mRNA and may reflect potential molecular mechanisms implicated in schizophrenia and affective disorders.
INTRODUCTION Dopamine-and cAMP-regulated phosphoprotein of molecular weight 32 kDa (DARPP-32) has been implicated in the pathogenesis of schizophrenia because of its role as a molecular integrator of dopaminergic and glutaminergic signaling.
1 DARPP-32 is mainly expressed in neurons receiving dopaminergic input in a number of brain regions, particularly the caudate nucleus, putamen, nucleus accumbens and cerebellar cortex. [2] [3] [4] [5] [6] When DARPP-32 is phosphorylated at threonine (Thr) 34 by protein kinase A, it is converted into an inhibitor of a multifunctional serine/Thr protein phosphatase-1 (PP-1) and indirectly regulates the physiological activities of a number of downstream proteins by promoting their phosphorylation. 7 DARPP-32 contains four phosphorylation sites, Thr34, Thr75, Serine (Ser) 102 and Ser137 (Figure 1 ), which regulate its activity. The signaling mediated by the dopamine D 1 receptor activates protein kinase A. In contrast, D 2 receptor stimulation induces dephosphorylation of DARPP-32 at Thr34 via calcium-/calmodulin-dependent protein phosphatase 2B (PP-2B; calcineurin).
Alternative splicing modulates gene function in the majority of organisms by increasing the diversity of expressed messenger RNA (mRNA) transcripts. Human brain displays the most abundant catalog of alternative transcripts compared with any other organ 8, 9 and splicing has an important role in brain development. Dysregulation of gene splicing has been implicated in a number of neurodevelopmental disorders, 10 including schizophrenia.
11 DARPP-32 has several splice variants, including one that encodes the full-length protein isoform (FL-DARPP-32) and another that encodes a truncated protein (t-DARPP-32) 12 ( Figure 1 ). t-DARPP-32 lacks the NH 2 -terminal Thr34 phosphorylation site and the PP inhibitory domain of DARPP-32, 13 which is critical for dopamine signaling and for regulating the activity of several PP-1-regulated proteins in the brain. t-DARPP-32 is frequently overexpressed in adenocarcinomas [14] [15] [16] [17] [18] and regulates cell growth and proliferation through the activation of the phosphoinositide-3-kinase/AKT pathway in human breast cancer cells. 19 Signaling properties of t-DARPP-32, its developmental pattern of expression in the brain and changes in psychiatric disorders have not yet been examined.
There have been a few postmortem brain studies of full-length DARPP-32 (but not t-DARPP-32) in psychiatric disorders, focused primarily on the dorsolateral prefrontal cortex (DLPFC). DARPP-32 protein levels were decreased in patients with schizophrenia and bipolar disorder [20] [21] [22] but mRNA results were inconsistent across the studies, showing no changes in schizophrenia, 23 a decrease in schizophrenia patients who died by suicide 24 and an increase in schizophrenia and bipolar disorder. 25 In other brain regions 1 changes in schizophrenia were also inconsistent, 22, [26] [27] [28] perhaps because most postmortem studies are limited by relatively small sample sizes.
Genetic association studies of PPP1R1B, the gene encoding DARPP-32 on chromosome 17q21 implicated by linkage studies in risk for schizophrenia 29 and bipolar disorder, 30 have generally not identified disease-associated single-nucleotide polymorphisms (SNPs) or haplotypes. [31] [32] [33] [34] [35] [36] The exception is a study from our laboratory, which found a frequent 7-SNP PPP1R1B haplotype associated with the schizophrenia in a family-based association analysis, and with enhanced performance on cognitive tests in the same families that depend on frontostriatal function, and also reduced neostriatal volume and increased frontostriatal interactions in multimodal imaging study of normal subjects. 11 We reported that this same haplotype predicted lower expression of full-length DARPP-32 isoform in a relatively small sample (n ¼ 38) of postmortem human DLPFC.
To extend this study to patients with schizophrenia, and examine regional and diagnostic specificity of the findings, we investigated expression of two major DARPP-32 transcripts, fulllength and truncated, in the DLPFC, hippocampus and caudate of 4700 subjects, including patients with schizophrenia and affective disorders, and conducted genotype expresssion analysis across the gene. We also compared temporal expression patterns of the two transcripts to gain insight into their potential roles in early brain development. Our data indicate that the expression of splice variants of DARPP-32 is altered in patients with schizophrenia and affective disorders, and shows some diagnostic specificity. The changes are transcript-and brain region-specific, and genetic variation in DARPP-32 influences alternative gene processing. These results underscore also the importance of using large sample sizes in postmortem brain studies.
MATERIALS AND METHODS

Human postmortem brain tissue collection
Postmortem brains were collected at the Clinical Brain Disorders Branch, National Institute of Mental Health (NIMH), with informed consent from the legal next-of-kin under NIMH protocol 90-M-0142 and at the Brain and Tissue Bank for Developmental Disorders of the National Institute of Child Health and Human Development under contracts NO1-HD-4-3368 and NO1-HD-4-3383. Clinical characterization, neuropathological screening, toxicological analyses, and dissections of the DLPFC and hippocampus were performed as previously described. 37 All DSM-IV Axis I lifetime psychiatric diagnoses were obtained using a combination of data from a telephone screening on the day of donation with next-of-kin, police, autopsy and toxicology reports, psychiatric records, family informant interviews with next-of-kin (NIMH psychological autopsy interview and the severe combined immunodeficiency) and/or interviews with psychiatric treatment providers. A psychiatric narrative summary was compiled from these data, which was reviewed by two board-certified psychiatrists. With respect to the major depressive disorder (MDD) cohort (n ¼ 138), 64.5% of cases met criteria for MDD, recurrent, severe, without psychotic features, 21% of cases met criteria for MDD, recurrent, severe, with psychotic features, 13% met criteria for a single episode of MDD, and 1.4% of cases met criteria for dysthymic disorder. Furthermore, 63.8% of the MDD cohort died of suicide, and 10.9% of the MDD cohort died of an accidental overdose. Alcohol and/ or substance abuse/dependence comorbidity within this cohort was high (42%). The striatum including caudate, putamen and nucleus accumbens was identified on the frozen coronal slabs corresponding to the anterior one-third of the inferior temporal cortex and dissected from one hemisphere with a dental drill (Cat# UP500-UG33, Brasseler, Savannah, GA, USA). A total of 709 DLPFC samples from postmortem brains were used for this study. The set of the samples from non-psychiatric individuals consists of 326 subjects (N ¼ 220 M; 106 F) ranging from fetal weeks 14-20 (43 fetal subjects; N ¼ 22 M; 21 F) and early postnatal age to 85 years of age. Diagnostic analyses were carried out using 176 subjects with schizophrenia (N ¼ 111 M; 65 F), 61 subjects with bipolar disorder (N ¼ 36 M; 25 F), 138 subjects with MDD (N ¼ 79 M; 59 F) and controls (N ¼ 171 M; 73 F, 413 years). Demographic data for these samples are summarized in Table 1 . To address the question of regional specificity, 466 hippocampal samples and 177 caudate samples, which overlapped with the DLPFC samples (96 and 94%, respectively), were also used in this study. Caudate samples did not include subjects with major depression.
The information about neuroleptic and antidepressant medications in subjects with psychiatric disorders was acquired from toxicology testing as previously described, 37 and lithium medication records were obtained from the subjects' medical charts. Smoking history (habits at the time of death as reported by next-of-kin) was used to establish smoking status.
DNA collection and genotyping DNA was extracted from cerebellar tissues (Qiagen, Valencia, CA, USA). All brain samples were genotyped using Illumina Human 1M-Duo BeadChips (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. In this study, we examined 58 SNPs located in or near the PPP1R1B gene (Supplementary Table S1a ). The genotyping of an additional four SNPs, which were not on the Illumina platform but formed a previously described haplotype, was performed using Taqman assays (Applied Biosystems, Foster City, CA, USA) (Supplementary Table S1b ). To construct haplotypes for analyses of gene expression data, we used Haploview 3.2 software (http://www.broad.mit.edu/mpg/haploview/ index.php) and assigned haplotypes to individuals using PHASE 2.1 (http://www.stat.washington.edu/stephens/phase/download.html), separately in Caucasian and African American populations (frequencies in Supplementary Table S2 ).
Quantitative real-time PCR
The expression levels of two DARPP-32 transcripts were measured in postmortem DLPFC, hippocampus and caudate samples using quantitative real-time PCR on an ABI Prism 7900 sequence detection system with a 384-well format (Applied Biosystems) by a standard curve method using Taqman assays (Hs00259967_m1, which measures both FL and t-DARPP32, and Hs00938416_g1, which is specific for t-DARPP32). As expression of t-DARPP32 is 30-60-fold lower than of FL-DARPP32 in all three brain regions examined, we will further use the symbol of FL-for the sum of FL and t-DARPP32 measured by the assay Hs00259967_m1. The expression data were normalized to a geometric mean of three housekeeping genes, beta 2-microglobulin (B2M), beta glucuronidase and beta actin expression. 
Statistical analyses
Comparisons between groups were made by analysis of covariances (ANCOVAs) for each transcript with diagnosis, antemortem medication and genotype as independent variables, and sex, age at death, race, smoking status and RNA quality as covariates using STATISTICA version 7.1 (StatSoft, Tulsa, OK, USA). Fisher least significant difference post hoc comparisons were used to evaluate diagnostic group differences. All data were covaried by sex, age at death, race, smoking status and RNA integrity number, and Bonferroni corrections (Po0.05) were applied in the analysis of the SNP data.
RESULTS
Expression of DARPP-32 transcripts in the diagnostic groups
In the DLPFC, we found that the expression levels of FL-DARPP32 were significantly increased in major depression as compared with all other groups (ANCOVA:
Fisher LSD: by 20%, P ¼ 1.1E À 4 as compared with controls, P ¼ 0.01 as compared with schizophrenia; and P ¼ 0.02 as compared with bipolar disorder) (Figure 2a ). The expression of t-DARPP-32 was significantly increased in schizophrenia and bipolar disorder as compared with controls (ANCOVA:
, post hoc Fisher LSD: by 20%, P ¼ 3.4 E À 4, by 68%, P ¼ 9.4E À 10, respectively) ( Figure 2b ). The expression of t-DARPP-32 in bipolar disorder patients was also significantly higher than in patients with schizophrenia and patients with major depression (post hoc Fisher LSD:
The levels of FL-and t-DARPP32 correlated significantly in all three brain regions in all subjects (all Spearman r values were positive 40.6, P values ¼ oE À 17), and separately in the diagnostic groups (r values 40.4, P values oE À 05).
As other studies 23 have shown that suicide may be a factor in the analysis of gene expression data in the prefrontal cortex, we examined the differences in t-DARPP-32 expression between schizophrenia patients who died by suicide (SZ-S) with those who died of other causes (SZ-NS). t-DARPP-32 expression was significantly lower in SZ-S as compared with SZ-NS (MannWhitney U-test: P ¼ 0.014), although there were no differences in the expression of FL-DARPP-32. In a group of MDD patients, subjects who died by suicide had significantly lower expression of FL-and t-DARPP32 than patients who died of other causes (Mann-Whitney U-test: P ¼ 0.011). There were no differences in the expression of the two transcripts between bipolar patients who died by suicide (BP-S) and those who died of other causes (BP-NS), Supplementary Figure S1 .
In the hippocampus, the expression levels of FL-DARPP-32 were significantly increased only in bipolar disorder as compared with all other groups (ANCOVA: F (3381) ¼ 16.59, P ¼ 3.8E À 10, post hoc Fisher LSD: by 87%, P ¼ 3.0E À 9 as compared with controls, P ¼ 9.6E À 10 as compared with schizophrenia; and P ¼ 7.7E À 8 as compared with major depression) (Figure 2c ). The expression of t-DARPP-32 was also significantly increased only in bipolar disorder as compared with all other groups (ANCOVA: F (3382) ¼ 2.77, P ¼ 0.04, post hoc Fisher LSD: by 101%, P ¼ 0.02 as compared with controls, P ¼ 0.019 as compared with schizophrenia; and P ¼ 0.015 as compared with major depression) (Figure 2d ).
In the caudate, the expression levels of FL-DARPP32 were not different in patients with schizophrenia and bipolar disorder as compared with controls (ANCOVA: F (2165) ¼ 1.42, P ¼ 0.25) (Figure 2e ). There were also no differences in the expression of t-DARPP-32 between the groups (ANCOVA: (Figure 2f ).
There were no significant effects of smoking on expression levels of either transcript in the DLPFC and hippocampus, although smoking increased expression of FL-DARPP-32 and t-DARPP-32 in the caudate (ANCOVA: F (1165) ¼ 4.42, P ¼ 0.037, ANCOVA: F (1161) ¼ 5.78, P ¼ 0.017, respectively). There were also no significant effects of antipsychotic medication, antidepressants or lithium on the expression levels of the two transcripts in any brain region examined (Supplementary Table S3 ). In addition, the expression of FL-DARPP-32 was not altered in the rat frontal cortex in response to chronic treatment with the neuroleptic drugs, clozapine and haloperidol (ANOVA: F (6,55) ¼ 0.12, P40.9) (Supplementary Figure S2) .
Expression of DARPP-32 transcripts during the life span To investigate the developmental profile of expression of the two transcripts, we used samples from the DLPFC and the hippocampus of normal controls across almost the entire human life span, Abbreviations: AA, African American; CAUC, Caucasian; GW, gestational week; PMI, postmortem interval; RIN, RNA integrity number; NA, not applicable.
DARPP-32 in schizophrenia and affective disorders Y Kunii et al
from the 14th through 20th gestational week and from birth through old age (85 years of age) (See Table 1 for subject demographics). For the caudate, samples from subjects 413 years of age were used. In the DLPFC, the expression of FL-DARPP-32 was relatively high during the prenatal period, dropped at birth and then increased gradually throughout postnatal life until old age (Figure 3a) . In contrast, t-DARPP-32 was expressed at very low levels prenatally, increased sharply from birth to pubescent ages and continued to increase, albeit at a slower pace, throughout the rest of life (Figure 3b) . In contrast to high-positive correlations between the splice variants in adult control subjects and in all three diagnostic groups, there was no significant correlation between FL-DARPP32 and t-DARPP32 during development of the DLPFC (from the fetal period to 20 years of age, Spearman r ¼ 0.12, P40.1). In the hippocampus, both transcripts were expressed at very low levels prenatally, increased gradually from birth to pubescent ages and then remained at almost constant levels (Figures 3c and d) . In the caudate, which only included samples from subjects older than 13 years of age, there was no evidence for an increase in the expression of the two transcripts with aging (from 13 to 80 years of age) as in the DLPFC and to a lesser extent in the hippocampus (Figures 3e and f) . Repeated measures two-way ANOVA (mixed type, factors: periods (prenatal or postnatal) and brain regions (DLPFC or hippocampus)) revealed a significant interaction effect for the FL-DARPP ¼ 32 expression (F (1, 236) ¼ 10.96; P ¼ 1.1E À 3), but not for t-DARPP-32 (F (1, 236) ¼ 1.81; P ¼ 0.18), confirming our observation that only FL-DARPP-32 shows a different expression trajectory in the DLPFC than in the hippocampus (Supplementary Figure S4a) and that t-DARPP32 in both regions shows significantly lower expression during the prenatal period vs postnatal life (Mann-Whitney U-test: P ¼ 6.1E À 25 in DLPFC; P ¼ 2.0E À 15 in DLPFC (a, b) ,hippocampus (c, d),and caudate (e, f ) from control subjects (CONT), and patients with schizophrenia (SZ), bipolar disorder (BP) and major depressive disorder (MDD) measured using quantitative real-time PCR. Data are normalized to a geometric mean of three housekeeping genes, beta 2-microglobulin (B2M), beta glucuronidase (GUSB) and beta actin (ACTB) expression. The asterisks over the bars indicate the significant differences compared with controls using a post hoc Fisher LSD test. DLPFC, dorsolateral prefrontal cortex. Figure S4b) . These findings are summarized in a schematic overview (Figure 4) .
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Effects of DARPP-32 genotype on expression of DARPP-32 transcripts
We examined the effects of 58 PPP1R1B SNPs on the mRNA expression levels of DARPP-32 splice variants in a large cohort of patients and controls from mainly two ethnic groups, Caucasians and African Americans. Twenty five of these SNPs were highly correlated (r 2 40.8). We also examined the effects of the previously identified 7-SNP haplotype, which predicted the mRNA expression of full-length DARPP-32 isoform in a smaller sample of postmortem DLPFC obtained from Caucasian subjects, 11 and was associated with schizophrenia and with cognitive performance in a clinical study.
In the DLPFC in the whole cohort, we found that six SNPs predicted expression of t-DARPP-32, including three SNPs that were previously associated with schizophrenia and with cognitive and imaging phenotypes 11 ( Figure 5a, Supplementary Figure S5 ).
In particular, rs907094 and rs3764352, which were in complete linkage disequilibrium, showed an allele dose-dependent effect (ANCOVA: F (2563) ¼ 8.54, P ¼ 2.2E-4) ( Figure 5b) ; individuals homozygous for the G allele at rs907094 and rs3764352 had significantly higher expression than heterozygous A/G individuals (P ¼ 0.04), who had also significantly higher expression than homozygous A individuals (P ¼ 1.1E À 3). Furthermore, we also found a significant effect of SNP rs879606 (not in linkage disequilibrium with the two SNPs described above) on the expression of t-DARPP-32 mRNA (ANCOVA: F (2562) ¼ 7.24, P ¼ 7.8E-4) (Figure 5c ). Individuals homozygous for the A allele at rs879606 had significantly higher expression than homozygous G individuals (P ¼ 7.4E À 4).
To address the possibility that either antipsychotics or lithium might have contributed to the observed effects, we conducted genetic association analysis in subjects who had no history of treatment with antipsychotics or lithium (all controls and major depressive patients). Similarly to the effects in all subjects, t-DARPP-32 expression in this cohort was associated with the genotypic variants at rs907094 and rs3764352 (ANCOVA: F 
Further analysis revealed a significant impact of the PPP1R1B haplotype, identified from clinical and cognitive associations, 11 on t-DARPP-32 but not FL-DARPP-32 expression. In accordance with the SNP analysis, expression of t-DARPP-32 was highest for carriers of the less frequent (GATGTCA) haplotype and lower for the homozygotes of the frequent (CGCACTC) haplotype and for subjects heterozygous for CGCACTC in combination with a rare haplotype (F(2270) ¼ 3.41, P ¼ 0.035, Supplementary Figure S6) . There was no impact of haplotypes on FL-DARPP-32 expression in this cohort (all P-values 40.5).
There were no significant associations (or trends) between any SNPs, genotypes or haplotypes examined in this study and the mRNA expression levels of DARPP-32 splice variants in the hippocampus and caudate in all subjects or in any of the diagnostic or race group separately.
DISCUSSION
In this study, we show that the expression of t-DARPP-32 is significantly increased in the DLPFC of patients with schizophrenia and of patients with bipolar disorder, that these alterations are region-specific and that the expression of t-DARPP-32 in the DLPFC is associated with genetic variants previously linked to schizophrenia and to cognitive functioning in an earlier study. Expression of full-length DARPP-32 transcript also showed notable regional and diagnostic specificity; FL-DARPP-32 was upregulated in the DLPFC but not hippocampus in major depression, and vice versa in bipolar disorder. This is consistent with at least some other postmortem molecular studies, which implicate prefrontal cortex in major depression 38 and hippocampus in bipolar disorder. 39 Moreover, we show that the expression of t-DARPP-32 in the DLPFC and hippocampus increases dramatically from the fetal period to postnatal age, suggesting that t-DARPP-32 may have a role in the development of monaminergic innervation at the transition from pre-to postnatal age. It is also possible that this increase simply reflects maturation of monaminergic connections. As t-DARPP-32 appears to interfere with protein kinase A inhibition by FL-DARPP-32 in a dominant-negative fashion 40 and thus activates phosphoinositide-3-kinase/AKT pathway signaling, 20 it may promote neurogenesis in the hippocampus 41 and dendritogenesis in the neocortex. 42 Upregulation of t-DARPP-32 may also lead to attenuation of dopamine signaling because t-DARPP-32 lacks the Thr 34 phosphorylation site and PP-1 inhibitory domain, which are critical for dopamine signaling in the brain. As t-DARPP-32 and FL-DARPP-32 have antagonistic effects on responses to anticarcinogenic agents and anti-apoptotic action, 13, 19, 40, 43 it is possible that these two transcripts have also antagonistic effects on the efficiency of dopamine system. Thus, it appears feasible that changes in t-DARPP-32 expression in the DLPFC may affect cognitive functions by altering dopamine signaling. This notion is further corroborated by the genetic findings. The minor alleles at rs907094, rs3764352 and rs879606 that have been associated with worse cognitive functioning across multiple domains 12 predict higher expression of t-DARPP-32 and their impact is specific to the DLPFC, a critical brain region for complex cognitive behaviors, personality, decision making and orchestration of thoughts and actions. Interestingly, a recent imaging report indicated that the carriers of minor alleles at rs907094, rs3764352 and rs879606 show lower connectivity within the network of brain regions (inferior frontal gyrus, parahippocampal gyrus and putamen) as compared with major allele homozygotes during associative emotional learning, posited to be dependent on the integration between glutamate and dopamine signaling. 44 Two other reports showed that genetic variation at rs907094 has been associated with processing of anger 45 and reward learning; 46 again, minor allele carriers showed worse cognitive function and learning.
There are several issues in the comparisons of the patient and control samples that require further attention. First, the confounding effects of medication and other illness-related factors on FL-DARPP-32 and t-DARPP-32 levels cannot be conclusively resolved in this study. Although we did not detect the effects of antipsychotics, antidepressants or lithium on FL-DARPP-32 and t-DARPP-32 expression levels and did not find effects of antipsychotics in the rat model, chronic administration of antidepressants and lithium (but not antipsychotics) has been reported to increase DARPP-32 immunoreactivity in the rat frontal cortex. 47 As rats also express t-DARPP-32, 48 further studies are warranted to examine the effects of chronic administration of psychotropic drugs on t-DARPP-32 expression in rat brains. It is thus possible that diagnostic differences (in particular, alterations in patients with bipolar disorder) might be owing at least in part to medication.
It should be noted that we have not measured t-DARPP-32 protein levels in this study. Our data from the subset of samples using a previously described antibody 20 that recognizes only fulllength DARPP-32 protein suggest, however, that there is no relationship between DARPP-32 protein immunoreactivity and mRNA levels (Supplementary Figure 3) . This may also be owing to poorly quantitative methods used to measure protein levels and/ or confounding factors affecting protein stability. In general, postmortem studies in patients should be viewed with caution with regard to the difficulty to control disease-related factors that may potentially affect the analyses. Second, our current results on the expression of DARPP-32 isoforms are somewhat inconsistent with those published in the previous study from our group. 11 We have now shown that minor alleles at three SNPs as well as the less frequent seven-SNP haplotype strongly predict an upregulation of t-DARPP-32, and that the expression FL-DARPP-32 is not significantly associated with these SNPs or with the haplotype. This is in contrast to our earlier results. One possibility is population heterogeneity or the influence of other non-genetic factors. This possibility is supported by the fact that the subset of the same Caucasian subjects/carriers of the frequent haplotype from the previous study does again show a trend for the upregulation of FL-DARPP-32 (data not shown), although the results for the whole cohort are not significant (there was a high correlation between the previous data and the current ones, r ¼ 0.77). Another possibility is that our previous study might have been underpowered to detect differences with modest effect sizes.
Third, it should be noted that the associations of t-DARPP-32 expression with genotypes are tissue-specific, indicating that genetic structure, although perhaps necessary, is not a sufficient factor for regulating t-DARPP-32 expression in the brain. It is possible that epigenetic mechanisms, such as DNA methylation, are involved. We have explored this possibility in a preliminary analysis in a subset of samples, assayed with the Illumina Infinium 27 K chip. These results indicate no relationship in the DLPFC between expression levels of the two DARPP-32 transcripts and methylation status at two CpG loci in the promoter region of PPP1RB1 that are contained on this chip (data not shown). To address the question of DNA methylation in more depth, we are currently examining a larger set of subjects using a platform that covers more CpG sites, including also intragenic loci within PPP1RB1.
In summary, our results show that the expression of the t-DARPP-32 transcript is altered in the postmortem brains of patients with schizophrenia and bipolar disorder, and, selectively in prefrontal cortex, is associated with genetic variation in the PPP1R1B. Our results emphasize the importance of using large sample sizes in postmortem brain research focused on effects of genetic variation.
